RxDoctor Payments Data

Cheryl Cavalli, DO

Family Medicine · Pueblo, CONPI 1306841325

Payments from drug & device makers

$4,634in general payments, 2019–2025

Across 253 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$879
  • Johnson & Johnson$594
  • Pfizer$566
  • GSK$542
  • AstraZeneca$138
  • plus $907 from 21 others

What the payments were for

  • Food & beverage$4,623100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,634 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$66,587
Medicare patients
247
Services billed
1,811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide92$136,085
EliquisApixaban112$104,320
JardianceEmpagliflozin48$58,825
OzempicSemaglutide25$45,478
XareltoRivaroxaban12$20,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,735
MyrbetriqMirabegron22$17,673
TrulicityDulaglutide18$15,738
FarxigaDapagliflozin Propanediol12$13,638
InvokanaCanagliflozin12$6,991
ArexvyRsvpref3 Antigen/As01e/Pf22$6,829
SynthroidLevothyroxine Sodium76$4,841
Estradiol81$4,806
Novolog FlexpenInsulin Aspart11$4,328
Levothyroxine Sodium483$4,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$33$151,823110 claims
PfizerEliquis$566$104,320112 claims
Novo NordiskOzempic$879$45,47825 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$542$30,11262 claims
Johnson & JohnsonXarelto, Invokana$594$27,81824 claims
Astellas Pharma US IncMyrbetriq$92$17,67322 claims
AstraZenecaFarxiga$138$13,63812 claims
AbbVieSynthroid$1,009$4,84176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →